Literature DB >> 18654122

Adrenalectomy improves arterial stiffness in primary aldosteronism.

Branislav Strauch1, Ondrej Petrák, Tomás Zelinka, Dan Wichterle, Robert Holaj, Mojmír Kasalický, Libor Safarík, Ján Rosa, Jirí Widimský.   

Abstract

BackgroundAldosterone has been shown to substantially contribute to the accumulation of different types of collagen fibers and growth factors in the arterial wall, which increase wall stiffness. We previously showed that arterial wall stiffness is increased in primary aldosteronism (PA) independently of concomitant hypertension. This study was aimed at assessing the effects of specific treatment of PA on the arterial stiffness.MethodsTwenty-nine patients with confirmed PA (15 with aldosterone-producing adenoma treated by unilateral laparoscopic adrenalectomy, 14 treated with spironolactone (mainly idiopathic aldosteronism) were investigated by Sphygmocor applanation tonometer (using measurement of carotid-femoral pulse wave velocity (PWV) and augmentation index (AI)) at the time of the diagnosis and then approximately 1 year after the specific treatment.ResultsThe office blood pressure (BP) decreased from 167 +/- 18/96 +/- 9 to 136 +/- 12/80 +/- 7 mm Hg after adrenalectomy (P = 0.001), and from 165 +/- 21/91 +/- 13 to 151 +/- 22/88 +/- 8 mm Hg (not significant (n.s.)) on spironolactone. The mean 24-h BP decreased from 150 +/- 18/93 +/- 11 mm Hg to 126 +/- 17/80 +/- 10 mm Hg after adrenalectomy (P < 0.01), and from 155 +/- 16/94 +/- 12 to 139 +/- 18/88 +/- 8 mm Hg (n.s.) on spironolactone. The PWV significantly decreased after surgery from 9.5 +/- 2.7 m/s to 7.6 +/- 2 m/s (P = 0.001), and the AI (recalculated for heart rate 75/min) decreased significantly from 27 +/- 10 to 19 +/- 9% (P < 0.01). On the other hand, we did not find significant change of arterial stiffness indices in patients treated with spironolactone (PWV: 9.3 +/- 1.6 m/s vs. 8.8 +/- 1.3 m/s (n.s.); AI: 25 +/- 9% vs. 25 +/- 8% (n.s.)).ConclusionsSurgical but not conservative treatment of PA led to a significant decrease of BP and arterial stiffness parameters.American Journal of Hypertension (2008). doi:10.1038/ajh.2008.243American Journal of Hypertension (2008); 21, 10, 1086-1092. doi 10.1038/ajh.2008.243.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18654122     DOI: 10.1038/ajh.2008.243

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  28 in total

1.  Alterations in vascular function in primary aldosteronism: a cardiovascular magnetic resonance imaging study.

Authors:  P B Mark; S Boyle; L U Zimmerli; E P McQuarrie; C Delles; E M Freel
Journal:  J Hum Hypertens       Date:  2013-07-25       Impact factor: 3.012

2.  Outcome of surgical treatment of primary aldosteronism.

Authors:  Marilisa Citton; Giovanni Viel; Gian Paolo Rossi; Franco Mantero; Donato Nitti; Maurizio Iacobone
Journal:  Langenbecks Arch Surg       Date:  2015-01-08       Impact factor: 3.445

Review 3.  Aldosterone excess and resistant hypertension: investigation and treatment.

Authors:  Michael Stowasser
Journal:  Curr Hypertens Rep       Date:  2014-07       Impact factor: 5.369

4.  Eplerenone improves endothelial function and arterial stiffness and inhibits Rho-associated kinase activity in patients with idiopathic hyperaldosteronism: a pilot study.

Authors:  Shinji Kishimoto; Kenji Oki; Tatsuya Maruhashi; Masato Kajikawa; Shogo Matsui; Haruki Hashimoto; Yuji Takaeko; Yasuki Kihara; Kazuaki Chayama; Chikara Goto; Yoshiki Aibara; Farina Mohamad Yusoff; Ayumu Nakashima; Kensuke Noma; James K Liao; Yukihito Higashi
Journal:  J Hypertens       Date:  2019-05       Impact factor: 4.844

5.  A retrospective study of laparoscopic unilateral adrenalectomy for primary hyperaldosteronism caused by unilateral adrenal hyperplasia.

Authors:  Shao-bo Jiang; Xu-dong Guo; Han-bo Wang; Ruo-zhen Gong; Hui Xiong; Zheng Wang; Hai-yang Zhang; Xun-bo Jin
Journal:  Int Urol Nephrol       Date:  2014-02-02       Impact factor: 2.370

Review 6.  Approach to the surgical management of primary aldosteronism.

Authors:  Maurizio Iacobone; Marilisa Citton; Giovanni Viel; Gian Paolo Rossi; Donato Nitti
Journal:  Gland Surg       Date:  2015-02

7.  2022 Guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the Management of Hypertension.

Authors:  Tzung-Dau Wang; Chern-En Chiang; Ting-Hsing Chao; Hao-Min Cheng; Yen-Wen Wu; Yih-Jer Wu; Yen-Hung Lin; Michael Yu-Chih Chen; Kwo-Chang Ueng; Wei-Ting Chang; Ying-Hsiang Lee; Yu-Chen Wang; Pao-Hsien Chu; Tzu-Fan Chao; Hsien-Li Kao; Charles Jia-Yin Hou; Tsung-Hsien Lin
Journal:  Acta Cardiol Sin       Date:  2022-05       Impact factor: 1.800

8.  Predictors of successful outcome after adrenalectomy for primary aldosteronism.

Authors:  Wei Wang; WeiLie Hu; XiaoMing Zhang; BangQi Wang; Chen Bin; Hai Huang
Journal:  Int Surg       Date:  2012 Apr-Jun

Review 9.  Management of hypertension in primary aldosteronism.

Authors:  Anna Aronova; Thomas J Fahey; Rasa Zarnegar
Journal:  World J Cardiol       Date:  2014-05-26

10.  Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study.

Authors:  Gregory L Hundemer; Gary C Curhan; Nicholas Yozamp; Molin Wang; Anand Vaidya
Journal:  Lancet Diabetes Endocrinol       Date:  2017-11-09       Impact factor: 32.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.